Sun Pharma to Declare Q4 Results on May 22, 2025
ECONOMY & POLICY

Sun Pharma to Declare Q4 Results on May 22, 2025

Sun Pharmaceutical Industries will announce results for the fourth quarter ended March 31, 2025, on May 22, 2025. The Company will conduct an hour-long call at 06.30 pm IST on May 22, 2025, where senior management will discuss the Company’s performance and answer questions from participants. To participate in this conference call, please pre-register yourself on the below link and dial the numbers provided below, five to ten minutes ahead of the scheduled start time. The operator will provide instructions on asking questions before the call. You can also hear the call via an audio webcast, details of which will be announced later on the Company website, www.sunpharma.com. A transcript of this conference call will also be available on the website.

Sun Pharma is the world’s leading specialty generics company with a presence in Specialty, Generics and Consumer Healthcare products. It is the largest pharmaceutical company in India and is a leading generic company in the US as well as Global Emerging Markets. Sun’s high growth Global Specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for over 18% of company sales. The company’s vertically integrated operations deliver high-quality medicines, trusted by physicians and consumers in over 100 countries. Its manufacturing facilities are spread across six continents. Sun Pharma is proud of its multi-cultural workforce drawn from over 50 nations.

Sun Pharmaceutical Industries will announce results for the fourth quarter ended March 31, 2025, on May 22, 2025. The Company will conduct an hour-long call at 06.30 pm IST on May 22, 2025, where senior management will discuss the Company’s performance and answer questions from participants. To participate in this conference call, please pre-register yourself on the below link and dial the numbers provided below, five to ten minutes ahead of the scheduled start time. The operator will provide instructions on asking questions before the call. You can also hear the call via an audio webcast, details of which will be announced later on the Company website, www.sunpharma.com. A transcript of this conference call will also be available on the website.Sun Pharma is the world’s leading specialty generics company with a presence in Specialty, Generics and Consumer Healthcare products. It is the largest pharmaceutical company in India and is a leading generic company in the US as well as Global Emerging Markets. Sun’s high growth Global Specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for over 18% of company sales. The company’s vertically integrated operations deliver high-quality medicines, trusted by physicians and consumers in over 100 countries. Its manufacturing facilities are spread across six continents. Sun Pharma is proud of its multi-cultural workforce drawn from over 50 nations.

Next Story
Real Estate

Häfele unveils Profin aluminium profiles for modern kitchens

Häfele has launched its Profin range of aluminium profiles, designed to enhance open kitchen layouts gaining popularity in urban homes. With shrinking living spaces and the rise of micro-living, kitchens are increasingly becoming integral parts of living areas. This demands cabinetry that is both functional and visually seamless. The Profin range offers a modern solution, combining aesthetics with precision engineering. It includes four product categories—Gola Profiles, Stack Modular Shelving, Rail Door Profiles, and Strike Shelving System—catering to varied functional and design nee..

Next Story
Resources

CIPL to invest Rs 4 billion in phosphoric acid plant

Caitlyn India (CIPL) will invest Rs 4 billion to set up a 50,000 TPA integrated phosphoric acid plant in southern India. The company is scouting port-accessible sites and plans to commission the facility by FY 2027. The project will span 30–50 acre and aims to reduce India's dependency on imported phosphoric acid. The plant will adopt hemihydrate–dihydrate (HH-DH) technology, enabling high-purity phosphoric acid production with cleaner gypsum by-products. A captive sulphuric acid unit will be included for operational efficiency. Initially, output will be supplied to domestic fertilise..

Next Story
Equipment

TKIL Industries, HOPPECKE partner for rail battery systems in India

TKIL Industries (formerly thyssenkrupp Industries India) has signed an exclusive agreement with Germany-based HOPPECKE Batterien GmbH & Co. to develop battery systems for India’s growing rail sector. The partnership aims to deliver innovative and sustainable energy storage solutions for metros, regional trains, and locomotives. The first joint project under this strategic alliance has already been secured and is expected to roll out in 2025. The collaboration comes at a time when India plans to double its electric locomotive capacity by 2030 and expand metro services from 23 to 31 c..

Advertisement

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement

Advertisement

Talk to us?